{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer&page=44",
    "query": {
      "condition": "Bladder Cancer",
      "page": 44
    },
    "page_size": 10
  },
  "pagination": {
    "page": 44,
    "page_size": 10,
    "total_count": 1096,
    "total_pages": 110,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer&page=45&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Bladder+Cancer&page=43&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T21:03:27.463Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03915405",
      "title": "KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urothelial Carcinoma"
      ],
      "interventions": [
        {
          "name": "KHK2455",
          "type": "DRUG"
        },
        {
          "name": "Avelumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kyowa Kirin, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2019-09-26",
      "completion_date": "2022-11-15",
      "has_results": false,
      "last_update_posted_date": "2024-04-25",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 5,
      "location_summary": "St. Petersburg, Florida • Iowa City, Iowa • Santa Fe, New Mexico + 2 more",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Santa Fe",
          "state": "New Mexico"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03915405"
    },
    {
      "nct_id": "NCT05742867",
      "title": "A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Urinary Bladder Neoplasms"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 115,
      "start_date": "2023-05-31",
      "completion_date": "2024-07-10",
      "has_results": false,
      "last_update_posted_date": "2025-01-23",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 1,
      "location_summary": "Morrisville, North Carolina",
      "locations": [
        {
          "city": "Morrisville",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05742867"
    },
    {
      "nct_id": "NCT04610671",
      "title": "Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Muscle-Invasive Bladder Carcinoma",
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "CG0070",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lee Moffitt Cancer Center and Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2020-10-26",
      "completion_date": "2024-07-25",
      "has_results": false,
      "last_update_posted_date": "2026-02-27",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04610671"
    },
    {
      "nct_id": "NCT00005644",
      "title": "Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Transitional Cell Cancer of the Renal Pelvis and Ureter",
        "Urethral Cancer"
      ],
      "interventions": [
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eastern Cooperative Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": null,
      "start_date": "2001-01-02",
      "completion_date": "2007-06-15",
      "has_results": false,
      "last_update_posted_date": "2023-06-22",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 16,
      "location_summary": "Cedar Rapids, Iowa • Kalamazoo, Michigan • East Orange, New Jersey + 10 more",
      "locations": [
        {
          "city": "Cedar Rapids",
          "state": "Iowa"
        },
        {
          "city": "Kalamazoo",
          "state": "Michigan"
        },
        {
          "city": "East Orange",
          "state": "New Jersey"
        },
        {
          "city": "Rochester",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005644"
    },
    {
      "nct_id": "NCT07000084",
      "title": "Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Non-Muscle Invasive Bladder Carcinoma",
        "Stage 0a Bladder Cancer AJCC v8",
        "Stage I Bladder Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "BCG Solution",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Biopsy of Bladder",
          "type": "PROCEDURE"
        },
        {
          "name": "Cystoscopy",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Transurethral Resection of Bladder Tumor",
          "type": "PROCEDURE"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 330,
      "start_date": "2025-07-17",
      "completion_date": "2028-12-05",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Gilbert, Arizona + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07000084"
    },
    {
      "nct_id": "NCT06630247",
      "title": "A Dose-escalation, Dose-finding, and Expansion Study of XL495 in Participants With Locally Advanced or Metastatic Solid Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Cancers",
        "Solid Tumor Cancer",
        "Solid Tumor Malignancy",
        "Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)",
        "Metastatic Solid Tumor",
        "Locally Advanced Solid Tumor",
        "Urothelial Cancer of Renal Pelvis"
      ],
      "interventions": [
        {
          "name": "XL495",
          "type": "DRUG"
        },
        {
          "name": "ADC cytotoxic agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Exelixis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2024-10-17",
      "completion_date": "2025-05-07",
      "has_results": false,
      "last_update_posted_date": "2025-06-25",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 10,
      "location_summary": "Denver, Colorado • New Haven, Connecticut • Washington D.C., District of Columbia + 6 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jefferson",
          "state": "Louisiana"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630247"
    },
    {
      "nct_id": "NCT06545955",
      "title": "A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-muscle Invasive Bladder Cancer With Carcinoma in Situ"
      ],
      "interventions": [
        {
          "name": "Nadofaragene Firadenovec",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ferring Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2024-10-01",
      "completion_date": "2030-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 40,
      "location_summary": "Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 34 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06545955"
    },
    {
      "nct_id": "NCT00005047",
      "title": "4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "cisplatin",
          "type": "DRUG"
        },
        {
          "name": "doxorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "vinblastine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 521,
      "start_date": "1997-08",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2017-06-08",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 73,
      "location_summary": "Glendale, Arizona • Phoenix, Arizona • Los Angeles, California + 47 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Greeley",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005047"
    },
    {
      "nct_id": "NCT02722538",
      "title": "Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Urinary Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Taris Biomedical LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2016-05-31",
      "completion_date": "2019-05-02",
      "has_results": false,
      "last_update_posted_date": "2023-09-18",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722538"
    },
    {
      "nct_id": "NCT05519878",
      "title": "Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Bladder Carcinoma",
        "Genitourinary System Neoplasm",
        "Kidney Carcinoma",
        "Prostate Carcinoma"
      ],
      "interventions": [
        {
          "name": "Best Practice",
          "type": "OTHER"
        },
        {
          "name": "Bright White Light Therapy",
          "type": "DEVICE"
        },
        {
          "name": "Occupational Therapy",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DEVICE",
        "BEHAVIORAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 224,
      "start_date": "2023-01-11",
      "completion_date": "2028-05-29",
      "has_results": false,
      "last_update_posted_date": "2026-10-19",
      "last_synced_at": "2026-10-29T21:03:27.463Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05519878"
    }
  ]
}